SCHEMBL1368477

SCHEMBL1368477

Cc1ccc(NC(=O)c2cc(-c3ccccc3Cl)no2)cc1C(=O)Nc1cnc2[nH]ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 2/20 0.54
NPC1 O15118 2/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CYP3A4 P08684 1/20 0.53
BRAF P15056 6/20 0.48
PIK3CA P42336 3/20 0.43
MTOR P42345 3/20 0.43
KIT P10721 1/20 0.42
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.40
CYP2C9 P11712 1/20 0.40
RAB9A P51151 1/20 0.39
ABL1 P00519 1/20 0.39
SRC P12931 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367333 0.92 NPC1 (0.57) MEN1KMT2ACYP1A2CYP2C19NPC1
SCHEMBL1366699 0.84 CYP1A2 (0.52) MEN1KMT2ACYP1A2CYP2C19NPC1
SCHEMBL17420246 0.78 NPC1 (0.55) KMT2ANPC1BRAFPIK3CAMTOR
SCHEMBL1366047 0.72 TNIK (0.55) MEN1KMT2ANPC1HPGDSMN1; SMN2
SCHEMBL1367703 0.72 PIK3CA (0.60) BRAFPIK3CAMTORKITABL1
SCHEMBL1367223 0.71 PIK3CA (0.49) MEN1KMT2ANPC1HPGDSMN1; SMN2
SCHEMBL1367425 0.71 KIT (0.56) BRAFPIK3CAMTORKITABL1
SCHEMBL1366429 0.71 PIK3CA (0.48) NPC1SMN1; SMN2BRAFPIK3CAMTOR
SCHEMBL13901987 0.70 CYP1A2 (0.77) MEN1KMT2ACYP1A2CYP2C19NPC1
SCHEMBL4114192 0.70 PIK3CA (0.55) BRAFPIK3CAMTORKITABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067599-B2 Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors HOFFMAN-LA ROCHE INC. (US) 2011-11-29 US claimed
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2009-12-24 US claimed
US-8067599-B2 Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors HOFFMAN-LA ROCHE INC. (US) 2011-11-29 US disclosed
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K5, MAP3K1, PRKACA MEN1 2591/4885KMT2A 1755/4885CYP1A2 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.